Clinical Trials Logo

Clinical Trial Summary

WiTNNess is designed to accurately document the natural course and variation of muscle disease caused by pathogenic changes of the TNNT1 gene. The primary aim of the study is to specify meaningful outcome measures for future clinical trials. WiTNNess is open to children and adults worldwide. Participants can choose to include their information once (cross-sectional cohort) or every few months (prospective cohort).


Clinical Trial Description

WiTNNess is an observational study that includes prospective and cross-sectional arms, both of which include people diagnosed with autosomal recessive TNNT1-associated muscle disease, commonly described as a form of infantile-onset (NEM5A) or childhood-onset (NEM5B) nemaline rod myopathy. The study's primary objective is to establish the nature and time course of disease outcomes under current treatment, so that these can later be compared to outcomes achieved with novel disease-modifying therapies (i.e., interventional trials). Participants from all over the world are welcome to enroll in either arm of the WiTNNess study. Following appropriate consent, those in the prospective arm are followed long-term. Recurring assessments are performed at the participant's home, the Clinic for Special Children, or a partnering clinical site, depending on the individual's particular circumstances. Basic assessments include vital signs, a physical exam, documentation of motor milestones, growth measurements, and blood chemistry values. Participant's may also undergo non-invasive ultrasound of the heart (echocardiogram) and one or more chest radiographs. Participants in the cross-sectional arm are contacted once after consent. Members of the WiTNNess study team partner with healthcare providers and family members to capture pertinent medical history, physical exam findings, growth metrics, and motor milestones at the time of contact. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06374719
Study type Observational [Patient Registry]
Source Clinic for Special Children
Contact Joelle Williamson, MPH
Phone 7176879407
Email jwilliamson@clinicforspecialchildren.org
Status Recruiting
Phase
Start date September 23, 2018
Completion date June 1, 2027

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03633565 - Comparative Study of Strategies for Management of Duchenne Myopathy (DM) Phase 4
Enrolling by invitation NCT02235220 - Reduction of Masticatory Muscle Activity by Restoring Canine Guidance N/A
Terminated NCT00278564 - Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases Phase 1
Completed NCT01642056 - EPI-743 for Metabolism or Mitochondrial Disorders Phase 1/Phase 2
Completed NCT02011282 - Electro-Neuro-Muscular Stimulation in ICU N/A
Completed NCT01702987 - Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS N/A
Active, not recruiting NCT01225614 - Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Phase 3
Recruiting NCT03749538 - Acute Transcranial Direct Current Stimulation in Patients With Systemic Autoimmune Myopathies N/A
Completed NCT02442986 - Neurological Outcome in Surgical and Non-surgical Septic Patients N/A
Recruiting NCT01022450 - Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients N/A
Withdrawn NCT00990834 - Muscle Characteristics Associated With Statin Therapy N/A
Active, not recruiting NCT00937001 - Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness N/A
Recruiting NCT01353430 - Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
Completed NCT03751644 - Peripherical Neuromuscular Electrical Stimulation in Systemic Autoimmune Myopathies N/A
Completed NCT02765828 - Identification of Tongue Involvement in Late-Onset Pompe Disease
Recruiting NCT05599568 - Repeated Bout Effect i Neuromuscular Diseases N/A
Withdrawn NCT02124070 - Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis Phase 1/Phase 2
Completed NCT02706314 - Impact of Human Blood Serum From Critically Ill Patients on Human Colon Neuronal Networks.
Recruiting NCT03042286 - SAPhIRE Statin Adverse Drug Reaction
Not yet recruiting NCT04941079 - Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Immune-related Myopathy (Myasthenia Gravis and Inflammatory Myopathy) Patients :a Prospective Observational Study